Research and Markets: Half Year 2012: Big Pharma Update

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9sbxtg/half_year_2012) has announced the addition of the "Half Year 2012: Big Pharma Update" report to their offering.

A half-year update to each member of the Big Pharma peer set, including forecasts for key products, pipeline updates and a strategic analysis of events over the first six months of the year

The Big Pharma Peer set - comprising those companies with annual revenues in excess of $10bn - posted H1 2012 sales of $196.6bn, down by $4.2bn over the total for H1 2011. Of the 12 companies covered in this analysis, half posted positive H1 2012 sales growth (over H1 2011) others were not so fortunate.

Scope

- Comparative performance of leading branded prescription pharmaceutical companies

- Snapshot of Big Pharma's current sales performance and outlook through to 2017

Highlights

- French company Sanofi saw the biggest advance in H1 2012 sales (over the year prior). The company enjoyed pharmaceutical sales growth from a range of products, but the biggest cause for the upturn in sales was Sanofi's reporting a full half year of Genzyme-sourced products.

- Both AstraZeneca and Pfizer posted the biggest H1 2012 sales losses compared to H1 2011, seeing their sales decline by $2.7bn each over the year prior. For both companies, generic sales erosion of flagship products was the primary cause of the sales deficit.

Reasons to Purchase

- Analyze the current and forecast performance of the Big Pharma peer set as a whole through a variety of key metrics

- Company-by-company analysis of performance through the first six months of 2012 and outlook for the future

Key Topics Covered:

SCOPE OF ANALYSIS

EXECUTIVE SUMMARY

- Key findings

- Half-year 2012 Big Pharma summary

- Big Pharma prescription pharmaceutical sales outlook

- - Therapy area analysis, 2011-17

- - Molecule type analysis, 2011-17

- - Launch/core/expiry analysis, 2011-17

- Big Pharma pipeline update

HALF-YEAR REVIEWS

- Key findings

- - Half-year 2012 key events

- - Key product sales performance

- - Pipeline update

- Abbott Laboratories

- AstraZeneca plc

- Bayer AG

- Bristol-Myers Squibb Co.

- Eli Lilly & Co.

- F. Hoffmann La Roche (Roche)

- GlaxoSmithKline plc

- Johnson & Johnson

- Novartis AG

- Merck & Co.

- Pfizer Inc.

- Sanofi

APPENDIX

Companies Mentioned

- Abbott Laboratories

- Akzo Nobel N.V.

- Amgen Inc.

- Bayer AG

- Bristol-Myers Squibb Company

- Evotec AG

- F. Hoffmann-La Roche Ltd

- GlaxoSmithKline Plc

- Hutchison 3G UK Limited

- Janssen Pharmaceuticals Inc.

- Legg Mason Inc.

- Merck KGaA

- Novartis AG

- Novo Nordisk A/S

- Pfizer Inc.

- Schindler Holding Ltd.

- Seattle Genetics Inc.

For more information visit http://www.researchandmarkets.com/research/9sbxtg/half_year_2012